Method for determining a prostate cancer risk, for distinguishing prostate cancer from benign prostate disease in a subject whatever, comprising the combination of two or more clinical parameters of the subject to determine the risk of prostate cancer, where one of these clinical parameters is the quantity of PSA-IgM occurring in a biological sample of the subject, combined with at least one additional clinical parameter that is not significantly correlated with PSA-IgM, characterized in that said method comprises the following steps: a. Determination by enzyme-linked immunosorbent assay of the quantity of PSA-IgM occurring in a biological sample of the subject b. Determination of prostate volume of the subject; c. Definition of the age of the subject; d. Conditional statement for patients with PSA-IgM/PV > 40 AU/ml 2, corresponding to a predictive probability for prostate cancer set to 90%, wherein patients having values greater than 40 AU/ml 2 are excluded from the method; e. Normalization of PSA-IgM with age and prostate volume; f. Determination of at least one of said clinical parameters of the subject that are not significantly correlated with PSA-IgM, as free PSA, PCA3, all precursors of the PSA, BPSA, and so on; g. Mathematical combination of said value of PSA-IgM with one or more of said clinical parameters of the subject, defining an index or predictive value; h. Correlation between this index or predictive value and a predetermined and established value with samples from patients with diagnosis of prostate cancer or known benign disease; i. Determination of the risk of prostate cancer based on said correlation. and wherein that PSA-IgM is normalized (PSA-IgMnorm) with age and prostate volume as: PSAIgM norm = 1 β 21 ⋅ PSAIgM β 32 ⋅ 1 β 31 ⋅ PV β 32 − 1 Ln β 41 ⋅ PV β 42 ⋅ β 11 ⋅ Age β 12 and wherein said mathematical combination determines a predictive probability value for prostate cancer according to an index (iXip), wherein: iXi = β 0 + β 1 ⋅ PSAIgM norm + β 21 ⋅ tPSA + 0.1 β 22 and iXip = 1 1 + e − iXi. and wherein Risk iXip Very Low <20.0% Low 20.0% - 30.0% Medium 30.0% - 50.0% High 50.0% - 80.0% Very High >80% a. Determination by enzyme-linked immunosorbent assay of the quantity of PSA-IgM occurring in a biological sample of the subject b. Determination of prostate volume of the subject; c. Definition of the age of the subject; d. Conditional statement for patients with PSA-IgM/PV > 40 AU/ml 2, corresponding to a predictive probability for prostate cancer set to 90%, wherein patients having values greater than 40 AU/ml 2 are excluded from the method; e. Normalization of PSA-IgM with age and prostate volume; f. Determination of at least one of said clinical parameters of the subject that are not significantly correlated with PSA-IgM, as free PSA, PCA3, all precursors of the PSA, BPSA, and so on; g. Mathematical combination of said value of PSA-IgM with one or more of said clinical parameters of the subject, defining an index or predictive value; h. Correlation between this index or predictive value and a predetermined and established value with samples from patients with diagnosis of prostate cancer or known benign disease; i. Determination of the risk of prostate cancer based on said correlation.